IFAM
AIMT

Institutional & Family Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Institutional & Family Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-52
Closed -$1K – 901
2019
Q2 		$1K Hold
52
– – ﹤0.01% 835
2019
Q1 		$1K Hold
52
– – ﹤0.01% 831
2018
Q4 		$1K Hold
52
– – ﹤0.01% 811
2018
Q3 		$1K Hold
52
– – ﹤0.01% 834
2018
Q2 		$1K Hold
52
– – ﹤0.01% 832
2018
Q1 		$2K Buy
+52
New +$1.83K ﹤0.01% 745

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Institutional & Family Asset Management's AIMT Position: Q3 2019 in Review

Institutional & Family Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 52 shares — an estimated $1K sold.

Institutional & Family Asset Management first reported a position in AIMT in Q1 2018 and held it in 6 quarters. The position peaked at $2K in Q1 2018. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Institutional & Family Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Institutional & Family Asset Management sold 52 Aimmune Therapeutics shares in Q3 2019, an estimated $1K.
  • Institutional & Family Asset Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 6 quarters.
  • Institutional & Family Asset Management's Aimmune Therapeutics position peaked at $2K in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Institutional & Family Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.